Boeing Co vs TransMedics Group Inc — how do they compare? Boeing Co trades at $234.13 (market cap $184.35B), while TransMedics Group Inc trades at $89.4 (market cap $3.10B). The key difference: Boeing Co is far larger — about 59.5× TransMedics Group Inc's market cap, and Boeing Co pays a 0.03% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| BA | TMDX | |
|---|---|---|
Market Cap | $184.35B | $3.10B |
Volume | 7,591,579 | — |
Sector | Industrials | Technology |
52-Week High | $252.15 | $150.42 |
52-Week Low | $179.12 | $61.99 |
Enterprise Value | $210.23B | $3.49B |
Dividend Yield | 0.03% | — |
Signals from Pluang's Aura AI — not financial advice
Boeing (BA) trades at $232.79, down 0.7% on the day, with a bullish technical signal supported by moving averages. The company reported revenue of $89.46B in 2025, swinging to a net income of $2.24B, and recent news highlights its strategic sale of non-core aviation technology units to Archer Aviation to sharpen focus on core aerospace and defense operations.
The outlook is positive with a consensus price target of $280.83, though high valuation ratios and volatile cash flows pose risks. Earnings momentum is mixed, with a recent Q2 2026 EPS miss, but analyst sentiment remains strongly bullish with 67% buy ratings.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
The Boeing Company, together with its subsidiaries, develops, produces, and markets commercial jet aircraft, as well as provides related support services to the commercial airline industry worldwide. The Company also researches, develops, produces, modifies, and supports information, space, and defense systems, including military aircraft, helicopters and space and missile systems.
Read more on BA →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →